Uses mass spectrometry-based quantitative proteomics to analyze the proteome in acute myeloid leukemia (AML) patient cells, aiming to unravel more of the complex biological processes behind AML and to find prognostic biomarkers which can guide therapeutic decisions.
Other research interests are cell-cell communication in the AML microenviroment and proteomic method optimization.
- 2019. The capacity of long-term in vitro proliferation of acute myeloid leukemia cells supported only by exogenous cytokines is associated with a patient subset with adverse outcome. Cancers. 1-22.
- 2019. High constitutive cytokine release by primary human acute myeloid leukemia cells is associated with a specific intercellular communication phenotype. Journal of Clinical Medicine.
- 2016. Systemic Analysis of Regulated Functional Networks. Methods in molecular biology. 287-310.
- 2016. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
- 2015. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
- 2014. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
- 2014. Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
- 2019. An overview on G protein-coupled receptor-induced signal transduction in acute myeloid leukemia. 5293-5316.
- 2018. Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. 13-24.
- 2017. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. 1053-1065.
Acute myeloid leukemia research